| Fezan Saleemi, | |
|
1301 3rd St, Suite 200, Wichita Falls, TX 76301-2245 | |
| (940) 767-5145 | |
| (940) 767-3027 |
| Full Name | Fezan Saleemi |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 11 Years |
| Location | 1301 3rd St, Wichita Falls, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043623986 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | BP10049155 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Heart Hospital Baylor Denton | Denton, TX | Hospital |
| Texas Health Presbyterian Hospital Denton | Denton, TX | Hospital |
| Medical City Denton | Denton, TX | Hospital |
| North Texas Medical Center | Gainesville, TX | Hospital |
| Baylor Scott & White Medical Center Grapevine | Grapevine, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medical Experts Of Texas, P.a. | 0143224170 | 3 |
News Archive
Low-income Americans with chronic obstructive pulmonary disease and those who lived in rural areas or the South or Midwest in 2008 had the highest rates of hospitalization for symptoms of the disease, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.
Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.
Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, announced a strategic collaboration with Merck, known as MSD outside of the United States and Canada, in which Arvinas' novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel therapeutics.
› Verified 4 days ago
| Entity Name | Medical Experts Of Texas, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730395989 PECOS PAC ID: 0143224170 Enrollment ID: O20060906000401 |
News Archive
Low-income Americans with chronic obstructive pulmonary disease and those who lived in rural areas or the South or Midwest in 2008 had the highest rates of hospitalization for symptoms of the disease, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.
Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.
Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, announced a strategic collaboration with Merck, known as MSD outside of the United States and Canada, in which Arvinas' novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel therapeutics.
› Verified 4 days ago
| Entity Name | Cogent Healthcare Of Texas Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992722953 PECOS PAC ID: 8628076924 Enrollment ID: O20061121000364 |
News Archive
Low-income Americans with chronic obstructive pulmonary disease and those who lived in rural areas or the South or Midwest in 2008 had the highest rates of hospitalization for symptoms of the disease, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.
Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.
Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, announced a strategic collaboration with Merck, known as MSD outside of the United States and Canada, in which Arvinas' novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel therapeutics.
› Verified 4 days ago
| Entity Name | Apogee Medical Group Texas Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558318071 PECOS PAC ID: 9436151792 Enrollment ID: O20070215000533 |
News Archive
Low-income Americans with chronic obstructive pulmonary disease and those who lived in rural areas or the South or Midwest in 2008 had the highest rates of hospitalization for symptoms of the disease, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.
Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.
Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, announced a strategic collaboration with Merck, known as MSD outside of the United States and Canada, in which Arvinas' novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel therapeutics.
› Verified 4 days ago
| Entity Name | Sound Inpatient Physicians Of Texas I, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831424563 PECOS PAC ID: 8729133640 Enrollment ID: O20090828000300 |
News Archive
Low-income Americans with chronic obstructive pulmonary disease and those who lived in rural areas or the South or Midwest in 2008 had the highest rates of hospitalization for symptoms of the disease, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.
Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.
Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, announced a strategic collaboration with Merck, known as MSD outside of the United States and Canada, in which Arvinas' novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel therapeutics.
› Verified 4 days ago
| Entity Name | Hospitalist Medicine Physicians Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629307095 PECOS PAC ID: 3476688318 Enrollment ID: O20100317001021 |
News Archive
Low-income Americans with chronic obstructive pulmonary disease and those who lived in rural areas or the South or Midwest in 2008 had the highest rates of hospitalization for symptoms of the disease, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.
Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.
Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, announced a strategic collaboration with Merck, known as MSD outside of the United States and Canada, in which Arvinas' novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel therapeutics.
› Verified 4 days ago
| Entity Name | Lonestar Hospital Medicine Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518237429 PECOS PAC ID: 6709049703 Enrollment ID: O20120530000620 |
News Archive
Low-income Americans with chronic obstructive pulmonary disease and those who lived in rural areas or the South or Midwest in 2008 had the highest rates of hospitalization for symptoms of the disease, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.
Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.
Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, announced a strategic collaboration with Merck, known as MSD outside of the United States and Canada, in which Arvinas' novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel therapeutics.
› Verified 4 days ago
| Entity Name | Ipc Healthcare Services Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023403011 PECOS PAC ID: 3971824939 Enrollment ID: O20150603001409 |
News Archive
Low-income Americans with chronic obstructive pulmonary disease and those who lived in rural areas or the South or Midwest in 2008 had the highest rates of hospitalization for symptoms of the disease, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.
Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.
Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, announced a strategic collaboration with Merck, known as MSD outside of the United States and Canada, in which Arvinas' novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel therapeutics.
› Verified 4 days ago
| Entity Name | Premier Phc Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538579347 PECOS PAC ID: 5698098812 Enrollment ID: O20150806011422 |
News Archive
Low-income Americans with chronic obstructive pulmonary disease and those who lived in rural areas or the South or Midwest in 2008 had the highest rates of hospitalization for symptoms of the disease, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.
Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.
Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, announced a strategic collaboration with Merck, known as MSD outside of the United States and Canada, in which Arvinas' novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel therapeutics.
› Verified 4 days ago
| Entity Name | Hospitalist Medicine Physicians Of Texas Lufkin Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881173060 PECOS PAC ID: 3375895063 Enrollment ID: O20181008001763 |
News Archive
Low-income Americans with chronic obstructive pulmonary disease and those who lived in rural areas or the South or Midwest in 2008 had the highest rates of hospitalization for symptoms of the disease, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.
Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.
Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, announced a strategic collaboration with Merck, known as MSD outside of the United States and Canada, in which Arvinas' novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel therapeutics.
› Verified 4 days ago
| Entity Name | Hospitalist Medicine Physicians Of Texas - Tyler, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861037590 PECOS PAC ID: 4880021211 Enrollment ID: O20200225001897 |
News Archive
Low-income Americans with chronic obstructive pulmonary disease and those who lived in rural areas or the South or Midwest in 2008 had the highest rates of hospitalization for symptoms of the disease, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.
Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.
Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, announced a strategic collaboration with Merck, known as MSD outside of the United States and Canada, in which Arvinas' novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel therapeutics.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Fezan Saleemi, 1301 3rd St, Suite 200, Wichita Falls, TX 76301-2245 Ph: (940) 767-5145 | Fezan Saleemi, 1301 3rd St, Suite 200, Wichita Falls, TX 76301-2245 Ph: (940) 767-5145 |
News Archive
Low-income Americans with chronic obstructive pulmonary disease and those who lived in rural areas or the South or Midwest in 2008 had the highest rates of hospitalization for symptoms of the disease, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.
Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.
Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, announced a strategic collaboration with Merck, known as MSD outside of the United States and Canada, in which Arvinas' novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel therapeutics.
› Verified 4 days ago
Dr. Ted Alexander, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 4327 Barnett Rd, Wichita Falls, TX 76310 Phone: 940-397-5400 Fax: 940-397-5482 | |
Brandon Christopher Ohman, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1620 8th Street, Wichita Falls, TX 76301 Phone: 940-764-5400 Fax: 940-764-5454 | |
Salman S Aleem, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2612 Southwest Pkwy, #129, Wichita Falls, TX 76308 Phone: 940-767-5145 Fax: 940-767-3027 | |
Anas Albrejawi Alhomsi, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1631 11th Street, Unit B, Wichita Falls, TX 76301 Phone: 940-263-3000 Fax: 940-263-3018 | |
Siby Sam, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1301 3rd St Ste 200, Wichita Falls, TX 76301 Phone: 940-767-8334 | |
Micheal Allan Moisant, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4412 Kell West Blvd, Wichita Falls, TX 76309 Phone: 940-696-0011 Fax: 940-696-2248 |